Delivery Order SPE2DE23D0008-SPE2D625F2SSH

Allergan USA Inc., a subsidiary of AbbVie Inc., received a $2,990 fixed-price delivery order from the Defense Logistics Agency (DLA) Medical Supply Chain on September 5, 2025, for Natrelle TE Smooth 133S-MX-14-T breast implants. This delivery order, with an ultimate completion date of September 9, 2025, represents a child award under one of Allergan's two significant Indefinite Delivery Vehicles (IDVs) established with DLA Troop Support Medical on December 8, 2022. The larger IDV supporting this award is valued at $13.5 million and covers Natrelle breast implants and surgical devices, structured with a one-year base period and four one-year option periods. The contract was awarded without a set-aside designation, reflecting Allergan's status as a sole-source provider of these specialized medical devices.

This award supports reconstructive and aesthetic surgical procedures across Department of Defense treatment facilities, Veterans Affairs hospitals, and Indian Health Service centers. The delivery order utilizes fixed-price pricing with economic price adjustment, enabling rapid fulfillment of critical surgical supplies for federal healthcare systems. As a key supplier of specialized medical devices to the military and veteran populations, Allergan USA Inc. continues to fulfill its role as the primary federal provider of Natrelle-branded breast implants through the DLA's Medical Supply Chain division. The compressed timeline between award date and completion date reflects the urgent nature of medical supply delivery for active surgical support requirements.